Chemours Earnings Call: Opteon Strength Amid Near-Term Strain

Chemours Company ((CC)) has held its Q4 earnings call. Read on for the main highlights of the call.

Chemours’ latest earnings call struck a cautiously optimistic tone. Management underscored robust cash generation, record growth in its Opteon refrigerant franchise, and a clear deleveraging path, while openly flagging near-term earnings pressure from outages, soft demand in certain segments, and elevated inventories that will weigh on early‑2026 cash flows.

Strong Q4 Free Cash Flow

Chemours generated $92 million of free cash flow in Q4 2025, which management framed as a proof point of the company’s underlying cash‑generation power. They argued this performance lays the groundwork for further free cash flow expansion in 2026 as cost savings, portfolio mix and capital discipline take hold.

Record TSS Opteon Growth and Mix Shift

The Thermal & Specialized Solutions segment delivered record Opteon sales, with Q4 refrigerant revenue up 37% year over year and 56% for all of 2025. Opteon now represents 75% of total refrigerant sales, up from 56% a year earlier, signaling a structural mix shift toward higher‑value, next‑generation products.

TSS Financial Momentum and Q1 Outlook

For Q1 2026, TSS is guiding to net sales growth of the mid‑20s to 30% sequentially, with Opteon volumes expected to jump 30–40%. Segment adjusted EBITDA is projected at $170–$185 million, and management expects TSS margins in 2026 to remain broadly consistent with 2025 despite some incremental operating costs.

Consolidated 2026 Guidance and Profitability Target

At the group level, Chemours expects 2026 net sales to grow 3–5% and adjusted EBITDA to land between $800 million and $900 million. For Q1, consolidated net sales are guided up 3–5% sequentially with adjusted EBITDA of $120–$150 million, implying a slow start to the year before a stronger second‑half contribution from TSS and APM.

Kuan Yin Site Sale to Accelerate Deleveraging

The company has agreed to sell its Kuan Yin site, expecting roughly $300 million in net proceeds that will be directed toward debt reduction. With this transaction, Chemours aims to push net leverage below 4x adjusted EBITDA by the end of 2026 and reiterated a longer‑term ambition to drive leverage under 3x.

Operational and Cost-Savings Progress

Chemours reported at least $125 million of gross controllable cost savings in 2025 as it tightened operations across the portfolio. The company also restructured its Titanium Technologies mining footprint, temporarily idling a North Florida mine, and is rolling out its Chemours business system to embed lean practices and enhance productivity.

TSS Capacity Expansion and Cost Upside

The ramp‑up of Corpus Christi capacity continues to be a key strategic lever for TSS, supporting growing Opteon demand. Management highlighted the longer‑term cost advantages from vertical integration and lower dependence on third‑party YF purchases, which should underpin margin resilience over time.

APM Demand Tailwinds in Technology End Markets

In Advanced Performance Materials, Chemours is seeing a healthier order book heading into Q1 2026 in semiconductors and data centers. Management called out strong interest in high‑purity PFA and solutions tied to AI and data center buildouts, which they expect to drive a gradual improvement in APM performance through 2026.

Washington Works Outage and Near-Term Hit

An unplanned outage at the Washington Works facility, tied to a prior local utility issue, forced a temporary shutdown and delayed restart that reduced capacity. The company estimates this disruption will carry a $20–$25 million negative EBITDA impact in Q1 2026, adding to near‑term earnings volatility.

APM Near-Term Weakness and Q1 Guide

Despite improving tech demand, APM remains pressured by cyclically weak auto and industrial construction markets that weighed on Q4 results. For Q1 2026, Chemours expects APM net sales to fall in the high‑teens percentage range sequentially, with adjusted EBITDA only around breakeven to $5 million.

TT Mineral Sales Slump and Profitability Pressure

Titanium Technologies faces a sharp step‑down in Q1 2026 mineral sales, guided down about 60% sequentially due to timing and mining changes, while TiO2 pigment volumes are seen off low single digits. TT adjusted EBITDA is expected to be only breakeven to $5 million, with roughly $17 million of extra costs from inventory, ore‑mix and lower utilization.

Missed Earnings Range and One-Time Costs

Management acknowledged they narrowly missed the low end of their earnings range for the quarter, citing incremental operating costs and noncash charges. They also accelerated liquidation and sale of select products, particularly in APM, to reduce inventories, emphasizing a “cash‑flow‑first” approach even at the expense of short‑term margins.

Elevated Inventory Levels and Working Capital Drag

Inventories remain elevated, about 7% higher year over year and roughly 50% above 2019 levels, rising from around $1.1 billion to about $1.6 billion. Management cautioned that normal seasonality plus this overhang could require up to $100 million of cash outflow in Q1 2026, creating a temporary drag on free cash flow.

TSS Incremental Operating Costs

Within TSS, Chemours absorbed roughly $22 million of extra costs in 2025 tied to liquid pooling and next‑generation refrigerant R&D. While these expenditures tempered some near‑term margin expansion, management framed them as strategic investments that should reinforce Opteon’s long‑run growth and competitive position.

Regional Demand and Market Share Pressure in Asia

TT revenues in Asia declined significantly over the year, with management pointing to large regional demand drops and tariff‑related friction in markets such as India. These factors contributed to lower TT volumes and revenues in the region, underscoring the segment’s sensitivity to global trade dynamics and localized pricing pressures.

Forward-Looking Guidance and Outlook

Looking ahead, Chemours expects Q1 consolidated net sales to rise 3–5% sequentially, with adjusted EBITDA between $120 million and $150 million and free cash flow use capped at $100 million. For 2026, the company is targeting 3–5% sales growth, $800–$900 million in adjusted EBITDA, free cash flow conversion above 25% and net leverage below 4x, driven by Opteon growth, cost‑outs and APM recovery.

Chemours’ earnings call painted a picture of a portfolio in transition, with strong structural growth in TSS and improving tech‑driven APM demand offset by near‑term headwinds in TT, outages and working capital. For investors, the story hinges on execution: delivering the promised cash flow and deleveraging while navigating a bumpy first half of 2026.